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Object. We present here the case of severe fetal anemia caused by anti-E antibody positive, which showed a favorable course only
withfetalintraperitonealadministrationofimmunoglobulin.Case.Themotherwas31yearsold,bloodtypeBRh:CCDee,gravida
1, with no history of transfusion. Anti-E antibody was detected in the maternal cross-match test at the 18th gestational week. In
percutaneous umbilical blood sampling, the umbilical blood hemoglobin level was 9.1g/dL and the result of the direct Coombs’
test was positive at the 26th gestational week. Immunoglobulin injection into fetal abdominal cavity (IFAC) was administered a
total 7 times. During the pregnancy, the indirect Coombs’ test showed a 131,072-fold increase. Conclusion. In this case, IFAC to
block the reticuloendothelial system Fc receptor was successful. This procedure is promising as one of the treatment options for
blood group incompatible pregnancy.
1.Introduction
Irregular antibodies are usually detected in 0.3% of all
pregnancies [1]. The management of Rh-D blood type
incompatible pregnancy is endorsed by the American Col-
lege of Obstetricians and Gynecologists (ACOG) [2, 3].
The established treatment for prevention of sensitization
during pregnancy is maternal administration of anti-D
immunoglobulin [4, 5]. However, the application of this
treatment for other blood-type incompatible pregnancies
has not been clearly indicated. In general, fetal transfusion
is recommended when anemia is conﬁrmed by ultrasonog-
raphy or percutaneous umbilical blood sampling. In the
present case, we administered immunoglobulin injection
into fetal abdominal cavity (IFAC) with severe anemia
caused by anti-E antibody. Following administration, the
anemia improved and the fetus showed a favorable postnatal
course.
2.Case
The patient was a 31-year-old female, B Rh:CCDee, gravida
1, parity 1, height 171cm, prepregnancy weight 72kg, pre-
pregnancy BMI 24.6, with no history of blood transfusion.
The father’s blood type was B Rh:ccDEE.
Anti-E antibody was detected at the early period of preg-
nancy,andthepatientwasreferredtoourhospitalatthe18th
gestational week. The result of the indirect Coombs’ test was
1:2,048, and a high antibody titer was maintained, as shown
in subsequent indirect follow-up Coombs’ tests performed
every 4 weeks. Although fetal hydrops did not develop,
middle cerebral artery peak systolic velocity was acutely el-
evated to 45.4cm/s at the 26th gestational week, suggesting
progressive anemia.
The patient was immediately admitted and fetal ane-
mia was evaluated by percutaneous umbilical blood sam-
pling (PUBS). The umbilical venous hemoglobin level was2 Case Reports in Obstetrics and Gynecology
Table 1: The clinical course.
Gestational
week (w)
Day after
birth (d)
Antibody
titer
MCA-PSV
(MoM)†
Hb
(g/dL) Ht (%) IgG
(mg/dL)
T-Bi1
(mg/dL)
Direct
Coombs’
test
Therapy
18 2,048 — — — — — — —
22 2,048 0.71 — — — — — —
25 4,096 1.15 — — — — — —
27 4,096 1.10 9.1 26.5 243 3.3 positive IFAC 68mL
29 4,096 1.67 8.8 25.9 547 2.9 positive IFAC 68mL
32 32,768 1.36 8.0 23.8 791 4.5 positive IFAC 84mL
33 131,072 0.98 8.5 25.9 1200 4.5 positive IFAC 100mL
34 32,768 0.82 8.7 26.6 1410 3.5 positive IFAC 100mL
34 32,768 0.95 8.2 25.3 1500 3.8 positive IFAC 150mL
35 16,384 1.37 8.3 25.5 2200 3.1 positive IFAC 100mL
36 65,536 — 13.6 43.1 8.9 positive
1 12.7 40.3 16.2
Exchange blood 
transfusion
Photo
therapy
2 11.2 32.6 10.6
3 11.9 34.2 12.2
4 11.1 32.3 12.5
5 12.2 36.2 11.1
10 9.7 28.6 10.9
21 8.5 24.6 9.3
MCA-PSV (MoM)†: middle cerebral artery-peek systolic velocity (multiple of median).
9.1g/dL, and the hematocrit level was 26.5%. The fetal
blood type was B Rh:CcDEEe, and the indirect Coombs’
test was positive. On the same day, immunoglobulin was
administered intraperitoneally to the fetus at a dose of 2g/kg
estimated body weight using a 25-gauge needle (Hanaco
Medical, Saitama, Japan). Diazepam 10mg, pentazocine
30mg, and ketamine 30mg were used for fetal anaesthesia.
More treatment sessions of IFAC were performed for a total
of 7 times. Fetal transfusion was not carried out at this
time. During IFAC treatment, the indirect Coombs’ test
value increased, transiently reaching 131,072-fold. Table 1
shows the hematologic proﬁle before and after IFAC. The
nonstress test showed a reassuring fetal status pattern during
treatment.
The mother delivered a male baby weighing 3,430g by
planned transvaginal delivery at 36 weeks. The Apgar scores
were 6/7, 1-minute/5-minutes, respectively. The hemoglobin
level was 13.6g/dL and the hematocrit level was 43.1% im-
mediately after birth. The indirect Coombs’ test was positive.
Postpartum, preventative phototherapy was carried out, but
at 2 days exchange transfusion was required (total-bilirubin
16.2mg/dL, LDH 590IU/L, hemoglobin 12.7g/dL, hemato-
crit 40.3%).
The baby was discharged on the 22th day. No signs
of anemia or developmental delay were identiﬁed until 18
months after birth.
3. Discussion
We previously reported the other case of fetal hemolytic
anemia with anti-M alloimmunization [6]. However, the
standard injection methods of immunoglobulin to fetuses
have not yet been established. In general, fetal transfusion
is required for the treatment of fetal anemia in blood
group incompatible pregnancy. Maternal immunoglobulin
administration has recently been suggested for the treatment
of blood type incompatible pregnancy to replace invasive
forms of treatment such as plasma exchange or fetal trans-
fusion. There have been reports that anti-D antibody titer
was stabilized 6-7 weeks after maternal immunoglobulin
administration and plasma exchange [7]. However, there is
as yet no report on the favorable prognosis in newborns only
with maternal immunoglobulin administration. A previous
report has described a patient with Rh-D incompatible
pregnancy continuously administered with maternal immu-
noglobulin at a dose of 1g/kg maternal body weight from
the 14th gestational week. Fetal transfusion was performed
concurrently from the 20th gestational week, and the baby
was delivered at the 34th gestational week [8]. In anoth-
er patient, although immunoglobulin administration was
started from the 10th gestational week, fetal transfusion was
technicallydiﬃcultandwasperformedonlyonceinthethird
trimester before birth [9]. Chitkara et al. reported that im-
munoglobulin therapy was ineﬀective in 4 patients with
Rh-D incompatible pregnancy [10]. However, there are few
negative reports on immunoglobulin therapy at present.
The eﬀects of immunoglobulin administration in blood
group incompatible pregnancy have not been fully clariﬁed
to date. However, the following eﬀects were suggested: (1)
prevent antibody combined cell destruction by blocking Fc
receptors in the reticuloendothelial system, (2) act as a neu-
tralizing antibody, (3) aid in the deposition of the immuneCase Reports in Obstetrics and Gynecology 3
complex, (4) increase the number of suppressor T-cells, and
(5) decrease the number of killer cells and peripheral lym-
phocytes [11–13]. Maternal immunoglobulin administra-
tionhasanadditionaleﬀectinpreventingtheplacentaltrans-
fer of irregular antibodies [14]. Furthermore, in vitro studies
have proven that immunoglobulin administration prevents
placental transfer of a pathogenic antibody [15]. However,
neutralization of an antibody transferred to the fetus cannot
be achieved by maternal immunoglobulin administration.
Postnatal immunoglobulin therapy has been reportedly
used for the treatment of blood type incompatible preg-
nancy. There has been a report on a patient treated with
0.5g/kg of immunoglobulin added to 20mL/kg of packed
RBC [16]. Although fetal transfusion is usually possible at
the 22nd gestational week, it is technically challenging and
incurs the risk of developing bradycardia. Furthermore, the
safety of blood preparations and changes in the potassium
ion should be considered. On the other hand, the advantages
ofIFACinclude lowercostthanRBCpreparations, lowerrisk
of infection because of the heating process, and no risk of
developing hemochromatosis.
From this background, we devised the immunoglobulins
administration in the fetal abdominal cavity. Although there
is a chance of puncturing the umbilical cord during IFAC,
havingobtained alive birthsafelyinthepresentcasethrough
the direct administration of immunoglobulin to the fetus
without the need for intrauterine blood transfusion, even
when the indirect Coombs’ test antibody titer had increased
as high as 131,072-fold, can be regarded as highly signiﬁcant.
The other methods for fetal immunoglobulin include
umbilicalvenousadministration.Althoughumbilicalvenous
administration is physiologically feasible, it carries the risk
of developing bradycardia from umbilical artery puncture,
aside from requiring expertise in the procedure. On the
otherhand,intraabdominaladministrationcreatesabroader
puncture area technically. Since intraabdominal adminis-
tered immunoglobulin is readily absorbed through subdi-
aphragmatic lymphatics, suﬃcient eﬀect can be expected.
We reported that immunoglobulins are incorporated into
the fetal circulation following IFAC [17]. The improved
safety of fetal treatment using 25-gauge needles has been
reported by Kawakami et al. [18]. Here, we used a high dose
of immunoglobulin (2g/kg) for the fetus, which is within
the therapeutic range for the Kawasaki disease [19]. The
administration of 2g/kg of immunoglobulin into the fetal
abdominal cavity did not induce symptoms of heart fail-
ure from volume overload, and complete immunoglobulin
absorption occurred after 3 days. Although the used dose is
not considered an overdose presently, additional studies are
required to determine the adequate dosage.
4. Conclusion
In this case, IFAC to block the reticuloendothelial system
Fc receptor was successful. This procedure is promising
as one of the treatment options for blood group incom-
patible pregnancy considering the merit of a heat-treated
product.
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